SAN DIEGO, California, April 21, 2021
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Yi Larson to its board of directors effective April 1, 2021. Ms. Larson has a highly accomplished biotechnology career having been a Managing Director of Healthcare Investment Banking at Goldman Sachs where she worked for over 12 years, followed by Chief Financial Officer at Turning Point Therapeutics, and currently serving as Chief Financial Officer at LianBio.
“RayzeBio is clearly establishing itself as the leader in the exciting field of radiopharmaceuticals,” said Ms. Larson. “The company has impressively built an infrastructure to drive innovation in the sector. The company’s strategy and aggressive execution have attracted financial backing from a broad base of top tier healthcare investors.”
“In my first meeting with Yi, I was immediately impressed by her intelligence and knew that I had to find a way to work with her,” said Ken Song, M.D., President and CEO of RayzeBio. “In addition to her financial expertise in the life sciences sector, she has corporate and business development strategic insight and has such a great personality that you want to spend time with her.”
RayzeBio also announces the expansion of its team with the following key employee hires:
- Derek Cole, PhD – Head of Discovery. With more than 25 years of drug discovery leadership in both peptide and small molecule chemistry, Derek has repeatedly proven that he can efficiently drive discovery programs into the clinic. At RayzeBio, Derek is leading an exceptional team of scientists and managing multiple collaboration partnerships to discover novel drug conjugates against our current set of clinically validated solid tumor targets.
- Kathie Huynh, CPA – Vice President of Finance. Kathie has 20 years of broad finance experience in life sciences having led both accounting as well as financial planning and analysis functions. In addition, Kathie has worked in both public and private companies and was recently an integral driver on the finance side for an initial public offering process.
- Daniel Kim, PharmD, MBA – Senior Director of Radiopharmaceuticals. Prior to joining RayzeBio, Dan was the head of radiopharmaceutical manufacturing at Novartis/AAA for Lutathera®, an approved targeted radiotherapy drug. Dan has 10 years of hands-on experience in the radiopharmaceutical field from being a nuclear pharmacist himself to then overseeing production, quality and regulatory compliance, and radiation safety in multiple facilities throughout the U.S.
“I am thoroughly impressed by Derek, Kathie, and Dan as they each bring deep expertise and passion for what they do,” said Dr. Song. “Derek and Dan have been working with RayzeBio since earlier this year and have contributed to tangible progress in our discovery and development efforts. Kathie is someone I have worked with before and so already know of her talents and ability to lead and execute.”
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com
Contact: email@example.com, (858) 257-3449